Divi’s Q2 FY27 Profit Jumps 64% as Revenue Hits ₹3,676 Crore
Divi’s Laboratories reported a 63.6% rise in Q2 FY27 consolidated profit to ₹1,127 crore as revenue from operations grew 35.4% to ₹3,676 crore.
Pharma
Schedule M Draft Sets Zero Microbial Growth for Sterile Drugs
Health Ministry proposes Schedule M changes requiring zero microbial growth in Grade A sterile drug areas, aligning Indian GMP rules with WHO TRS 1044.
AstraZeneca India to Launch Datverzo as Q2 Revenue Rises 30%
AstraZeneca Pharma India will launch Datverzo for HR-positive, HER2-negative breast cancer in November 2026 as Q2 FY27 revenue rose 30% to ₹729 crore.
Cancer Drug Price Cuts Start Nov 9, Saving ₹3,502 Crore a Year
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31%
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Symbiotec Signs 10-Year EU CDMO Deal for Alt Protein
Symbiotec signs a 10-year take-or-pay CDMO agreement with a European innovator for fermentation-based alternative protein at its Ujjain campus.
Aurobindo Pharma Q2 FY27: Record Revenue, Profit Up 32.5%
Aurobindo Pharma’s Q2 FY27 net profit rose 32.5% to ₹1,124 crore as revenue hit a record ₹10,263 crore on US and Europe growth and 12 USFDA approvals.
Centre Proposes Instant NSQ Drug Licence Suspension
Union Health Ministry proposes immediate suspension of drug manufacturing licences for NSQ findings on assay, dissolution, impurities or sterility.
Aarti Drugs Q2 FY27 Profit Jumps 83% on API, Formulation Growth
Aarti Drugs’ Q2 FY27 net profit rose 83% to ₹82.8 crore as revenue grew 27% to ₹828.8 crore and the EBITDA margin hit a near six-year high of 16.6%.
Lupin Q2 FY27: Sales Rise 14% but Net Profit Falls 22%
Lupin’s Q2 FY27 sales rose 14% to ₹7,785.5 crore, but net profit fell 22% to ₹1,155.3 crore as its EBITDA margin narrowed 770 basis points to 27.9%.
Evonile Pharma Q2 FY27: First Results After Novartis Exit
Evonile Pharma, formerly Novartis India, posted Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore as it builds its own field force.
Neuland Labs Q2 FY27 Profit Falls 47% as Margins Narrow
Neuland Labs’ Q2 FY27 profit fell 47% to ₹51.1 crore as income slipped 11%, while the API maker opened a new peptide plant and bought land in Kakinada.
Granules India Q2 FY27 Profit Rises 39% to ₹182 Crore
Granules India’s Q2 FY27 net profit rose 39% to ₹182 crore on 20% revenue growth, with three first-to-file ANDAs and five US launches lined up.
